newsfilter
← Latest News
PR Newswire·

Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data

Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO, June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc ana